GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ENCell Co Ltd (XKRX:456070) » Definitions » Net Income From Continuing Operations

ENCell Co (XKRX:456070) Net Income From Continuing Operations : ₩-13,910 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is ENCell Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. ENCell Co's net income from continuing operations for the three months ended in Mar. 2025 was ₩-4,648 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ₩-13,910 Mil.

ENCell Co Net Income From Continuing Operations Historical Data

The historical data trend for ENCell Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENCell Co Net Income From Continuing Operations Chart

ENCell Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
-6,696.77 -6,578.95 -45,566.95 -5,053.52 -15,209.84

ENCell Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Sep24 Dec24 Mar25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only -845.96 -2,903.33 -4,066.66 -5,195.19 -4,648.04

ENCell Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-13,910 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ENCell Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ENCell Co Ltd (XKRX:456070) » Definitions » Net Income From Continuing Operations
Comparable Companies
XKRX:251120 XKRX:214260 XKRX:338840 XKRX:299660 XKRX:376270 XKRX:048530 XKRX:311690 XKRX:278650 XKRX:084990 XKRX:321550 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
701 Yeongdong-daero, 11th floor, Gangnam-gu, Seoul, KOR
Website
http://www.encellinc.com
ENCell Co Ltd is a biopharmaceutical company. The company is engaged in conducting biopharmaceutical contract development and manufacturing (CDMO) service business and cell, gene therapy new drug development business for rare/incurable muscle diseases such as Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, and sarcopenia.

ENCell Co Headlines

No Headlines